文献速递妇科

促性腺激素释放激素激动剂联合高强度聚焦超声消融治疗子宫腺肌病的临床研究

Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study.
PubMed 文献 · BJOG · 2017-01-01

这项非随机前瞻性研究纳入79例子宫腺肌病患者,55例仅接受高强度聚焦超声(HIFU)消融(对照组),24例接受促性腺激素释放激素激动剂(GnRH-a)联合HIFU(研究组),随访6个月。结果显示联合组在降低血清CA125、子宫体积、腺肌病病灶体积、痛经评分和月经量方面优于单用HIFU组,不良反应无显著差异,但需进一步随访探索长期效果。

要点

  • GnRH-a联合HIFU较单用HIFU进一步降低血清CA125水平(P<0.05)。
  • 联合组子宫体积和腺肌病病灶体积在术后3、6个月较对照组下降更明显(P<0.05)。
  • 联合组痛经评分和月经量在术后3、6个月较对照组显著降低(P<0.05)。

核心结论

  • 短期随访结果表明,与单用HIFU消融相比,GnRH-a联合HIFU治疗子宫腺肌病可显著降低血清CA125水平、子宫体积、腺肌病病灶体积、月经量及痛经评分,改善临床结局;但需进一步随访以探索长期效果。

研究设计与样本

  • 非随机前瞻性研究,在单家医院的妇科微创中心开展,纳入79例子宫腺肌病患者,对照组55例仅接受HIFU治疗,研究组24例接受GnRH-a联合HIFU治疗,所有患者HIFU术后随访6个月。

主要发现

  • HIFU治疗前,两组血清CA125、CA19-9、白细胞介素-6(IL-6)水平、子宫体积、腺肌病病灶体积、月经量及痛经评分均无显著差异(P>0.05)。
  • HIFU治疗后两组血清CA125水平均显著下降,但研究组血清CA125水平仍显著低于对照组(P<0.05)。
  • HIFU治疗后两组子宫体积和腺肌病病灶体积均显著缩小,研究组在术后3个月和6个月缩小更明显(P<0.05)。
  • HIFU治疗后两组痛经评分和月经量均显著降低,研究组在术后3个月和6个月显著低于对照组(P<0.05)。
  • 两组不良反应发生率无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要进一步随访以探索长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study was to investigate the clinical efficacy of a gonadotrophin-releasing hormone agonist (GnRH-a) combined with high-intensity focused ultrasound (HIFU) ablation treatment for adenomyosis. DESIGN: A non-randomized prospective study. SETTING: Gynaecological Minimally Invasive Centre in a single hospital. POPULATION: Patients with adenomyosis. METHODS: Seventy-nine patients with adenomyosis were enrolled, including 55 patients in the control group treated with only HIFU and 24 patients in the study group treated with GnRH-a combined with HIFU. All the patients follow up 6 months after the HIFU procedure. The related parameters in the two groups were assessed before and 3 months as well as 6 months after treatment including serum levels of tumor marker and cytokine, volumes of uterine, adenomyotic lesion, and menstrual blood, as well as dysmenorrheal scores. MAIN OUTCOME MEASURES: Differences between the group treated with HIFU alone and the group treated with GnRH-a combined with HIFU. RESULTS: Before HIFU treatment, no significant difference was observed in serum levels of CA125, CA19-9, and interleukin-6 (IL-6), the volumes of uterine, adenomyotic lesion, and menstrual blood, as well as dysmenorrhea scores between the two groups. (P > 0.05). The serum CA125 levels significantly decreased in both groups after HIFU, but the serum CA125 levels in the study group were still significantly lower than those in the control group (P < 0.05). The volume of uterine and adenomyotic lesion significantly decreased in both groups after HIFU procedure, and decreased even more in the study group 3 and 6 months after treatment (P < 0.05). Dysmenorrhea scores and menstruation volumes significantly decreased in both groups after HIFU treatment. Moreover in the study group were significantly lower than those in the control group after 3 and 6 months (P < 0.05). No significant difference was observed in the rate of adverse effects between the two groups. CONCLUSIONS: The short-term follow-up results indicate that the combination of GnRH-a and HIFU treatment significantly decreased serum CA125 levels, volumes of uterine, adenomyotic lesion and menstrual blood, as well as dysmenorrhea scores, and improved the clinical outcomes compared with the HIFU ablation alone in patients with adenomyosis. However, the further follow-up is needed to explore the long-term effects. TWEETABLE ABSTRACT: A combination of GnRH-a with HIFU in the treatment of adenomyosis significantly decreased serum CA125 levels, uterine and adenomyotic lesion volumes, dysmenorrhea scores, and menstrual blood volumes.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Guo Y, Duan H, Cheng J, et al. Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study. BJOG. 2017. PMID: 28856862. doi:10.1111/1471-0528.14736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。